Last reviewed · How we verify
HUMAN C1-ESTERASE INHIBITOR
At a glance
| Generic name | HUMAN C1-ESTERASE INHIBITOR |
|---|---|
| Modality | Recombinant protein |
| Phase | FDA-approved |
| First approval | 2011 |
Approved indications
Common side effects
Key clinical trials
- Complement and Graft-versus-host Disease (NA)
- Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL) (PHASE2)
- Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks (PHASE3)
- Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection (PHASE2)
- C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks
- Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve Implantation (PHASE2)
- Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH) (PHASE2)
- Berinert (C1INH) vs Placebo for DGF/IRI (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HUMAN C1-ESTERASE INHIBITOR CI brief — competitive landscape report
- HUMAN C1-ESTERASE INHIBITOR updates RSS · CI watch RSS